The farnesoid X receptor: a potential target for expanding the therapeutic arsenal against kidney disease

References

• Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687–693.
   PubMed Web of Science ®Google Scholar
• Seol W, Choi HS, Moore DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol. 1995;9:72–85.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3:543–553.
   PubMed Web of Science ®Google Scholar
• Dussault I, Beard R, Lin M, et al. Identification of Gene-selective modulators of the bile acid receptor FXR. J Biol Chem. 2002;278:7027–7033.
   PubMed Web of Science ®Google Scholar
• Flatt B, Martin R, Wang T-L, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009;52:904–907.
   PubMed Web of Science ®Google Scholar
• Higashiyama H, Kinoshita M, Asano S. Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. Acta Histochem. 2008;110:86–93.
   PubMed Web of Science ®Google Scholar
• Hwang ST, Urizar NL, Moore DD, et al. Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. Gastroenterology. 2002;122:1483–1492.
   PubMed Web of Science ®Google Scholar
• Suh JM, Yu C-T, Tang K, et al. The expression profiles of nuclear receptors in the developing and adult kidney. Mol Endocrinol. 2006;20:3412–3420.
   PubMedGoogle Scholar
• Lee H, Zhang Y, Lee FY, et al. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J Lipid Res. 2006;47:201–214.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–191.
   PubMed Web of Science ®Google Scholar
• He F, Li J, Mu Y, et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res. 2006;98:192–199.
   PubMed Web of Science ®Google Scholar
• Li YTY, Swales KE, Thomas GJ, et al. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol. 2007;27:2606–2611.
   PubMed Web of Science ®Google Scholar
• Schote AB, Turner JD, Schiltz J, et al. Nuclear receptors in human immune cells: expression and correlations. Mol Immunol. 2007;44:1436–1445.
   PubMed Web of Science ®Google Scholar
• Serrano MA, Macias RIR, Briz O, et al. Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta. Placenta. 2007;28:107–117.
   PubMed Web of Science ®Google Scholar
• Chiang JYL. Negative feedback regulation of bile acid metabolism: impact on liver metabolism and diseases. Hepatology. 2015;62:1315–1317.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113:1408–1418.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Castellani LW, Sinal CJ, et al. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 2004;18:157–169.
   PubMed Web of Science ®Google Scholar
• Wang Y-D, Chen W-D, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48:1632–1643.
   PubMed Web of Science ®Google Scholar
• Liu Z-Q, Lee JN, Son M, et al. Ciliogenesis is reciprocally regulated by PPARA and NR1H4/FXR through controlling autophagy in vitro and in vivo. Autophagy. 2018;14:1011–1027.
   PubMed Web of Science ®Google Scholar
• Koutsounas I, Giaginis C, Theocharis S, et al. Receptor (FXR) from normal to malignant state. Histol Histopathol. 2012;27:835–853.
   PubMed Web of Science ®Google Scholar
• Giaginis C, Karandrea D, Alexandrou P, et al. High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma. Neoplasma. 2017;64:633–639.
   PubMed Web of Science ®Google Scholar
• Giaginis C, Tsoukalas N, Alexandrou P, et al. Clinical significance of farnesoid X receptor expression in thyroid neoplasia. Future Oncol. 2017;13:1785–1792.
   PubMed Web of Science ®Google Scholar
• Giaginis C, Koutsounas I, Alexandrou P, et al. Elevated Farnesoid X Receptor (FXR) and Retinoid X Receptors (RXRs) expression is associated with less tumor aggressiveness and favourable prognosis in patients with pancreatic adenocarcinoma. Neoplasma. 2015;62:332–341.
   PubMed Web of Science ®Google Scholar
• St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, et al. Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol. 2001;204:1673–1686.
   PubMed Web of Science ®Google Scholar
• Ballatori N, Christian WV, Lee JY, et al. OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology. 2005;42:1270–1279.
   PubMed Web of Science ®Google Scholar
• Boyer JL, Trauner M, Mennone A, et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1124–G1130.
   PubMed Web of Science ®Google Scholar
• Frankenberg T, Rao A, Chen F, et al. Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids. Am J Physiol Gastrointest Liver Physiol. 2006;290:G912–G922.
   PubMed Web of Science ®Google Scholar
• Landrier J-F, Eloranta JJ, Vavricka SR, et al. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes. Am J Physiol Gastrointest Liver Physiol. 2006;290:G476–G485.
   PubMed Web of Science ®Google Scholar
• Zollner G, Fickert P, Fuchsbichler A, et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol. 2003;39:480–488.
   PubMed Web of Science ®Google Scholar
• Zollner G, Wagner M, Moustafa T, et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol. 2006;290:G923–G932.
   PubMed Web of Science ®Google Scholar
• Marquardt A, Al-Dabet MM, Ghosh S, et al. Farnesoid X receptor agonism protects against diabetic tubulopathy: potential add-on therapy for diabetic nephropathy. J Am Soc Nephrol. 2017;28:3182–3189.
   PubMed Web of Science ®Google Scholar
• Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes. 2007;56:2485–2493.
   PubMed Web of Science ®Google Scholar
• Gui T, Gai Z. Genome-wide profiling to analyze the effects of FXR activation on mouse renal proximal tubular cells. Genom Data. 2015;6:31–32.
   PubMed Web of Science ®Google Scholar
• Zhang X, Huang S, Gao M, et al. Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice. Proc Natl Acad Sci U S A. 2014;111:2277–2282.
   PubMed Web of Science ®Google Scholar
• Xu S, Huang S, Luan Z, et al. Farnesoid X receptor is essential for the survival of renal medullary collecting duct cells under hypertonic stress. Proc Natl Acad Sci U S A. 2018;115:5600–5605.
   PubMed Web of Science ®Google Scholar
• Li S, Qiu M, Kong Y, et al. Bile acid G protein-coupled membrane receptor TGR5 modulates aquaporin 2-mediated water homeostasis. J Am Soc Nephrol. 2018;29:2658–2670.
   PubMed Web of Science ®Google Scholar
• Wang XX, Jiang T, Shen Y, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes. 2010;59:2916–2927.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ren L, Wang C, et al. Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed Wistar rats. Kidney Blood Press Res. 2012;36:85–97.
   PubMed Web of Science ®Google Scholar
• Wang XX, Jiang T, Shen Y, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol. 2009;297:F1587–F1596.
   PubMed Web of Science ®Google Scholar
• Gai Z, Gui T, Hiller C, et al. Farnesoid X receptor protects against kidney injury in uninephrectomized obese mice. J Biol Chem. 2016;291:2397–2411.
   PubMed Web of Science ®Google Scholar
• Wang XX, Wang D, Luo Y, et al. FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity. J Am Soc Nephrol. 2018;29:118–137.
   PubMed Web of Science ®Google Scholar
• Sun L, Halaihel N, Zhang W, et al. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002;277:18919–18927.
   PubMed Web of Science ®Google Scholar
• Jiang T, Wang Z, Proctor G, et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem. 2005;280:32317–32325.
   PubMed Web of Science ®Google Scholar
• Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol. 2006;17:2992–2998.
   PubMed Web of Science ®Google Scholar
• Magdy YM, El-Kharashi OA, El-Waseef D, et al. Insights into hepatic and renal FXR/DDAH-1/eNOS pathway and its role in the potential benefit of rosuvastatin and silymarin in hepatic nephropathy. Exp Mol Pathol. 2018;105:293–310.
   PubMed Web of Science ®Google Scholar
• Jin Z, Gu C, Tian F, et al. NDRG2 knockdown promotes fibrosis in renal tubular epithelial cells through TGF-β1/Smad3 pathway. Cell Tissue Res. 2017;369:603–610.
   PubMed Web of Science ®Google Scholar
• Langhi C, Pedraz-Cuesta E, Donate Y, et al. Regulation of N-Myc downstream regulated gene 2 by bile acids. Biochem Biophys Res Commun. 2013;434:102–109.
   PubMed Web of Science ®Google Scholar
• Zhao K, He J, Zhang Y, et al. Activation of FXR protects against renal fibrosis via suppressing Smad3 expression. Sci Rep. 2016;6:37234.
   PubMed Web of Science ®Google Scholar
• Lim AKH, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm. 2012;2012:146154.
   PubMed Web of Science ®Google Scholar
• Gai Z, Chu L, Xu Z, et al. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage. Sci Rep. 2017;7:9815.
   PubMed Web of Science ®Google Scholar
• Zhu J-B, Xu S, Li J, et al. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury. Eur J Pharmacol. 2018;838:60–68.
   PubMed Web of Science ®Google Scholar
• Glezerman IG, Jaimes EA. Chapter 11 Chemotherapy and kidney injury. In: Αmerican Society of Nephrology Onco-Nephrology Curriculum. Washington, DC: American Society of Nephrology, 2016. p. 1–10 [cited 2018 Aug 13]; Available from: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter11.pdf.
   Google Scholar
• Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334:115–124.
   PubMed Web of Science ®Google Scholar
• Bae EH, Choi HS, Joo SY, et al. Farnesoid X receptor ligand prevents cisplatin-induced kidney injury by enhancing small heterodimer partner. PLoS One. 2014;9:e86553.
   PubMed Web of Science ®Google Scholar
• Zordoky BNM, Anwar-Mohamed A, Aboutabl ME, et al. Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab Dispos. 2011;39:1440–1450.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu Y, Qi Y, et al. Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation. Toxicology. 2017;378:53–64.
   PubMed Web of Science ®Google Scholar
• Martin SJ, Sabina EP. Amelioration of anti-tuberculosis drug induced oxidative stress in kidneys by Spirulina fusiformis in a rat model. Ren Fail. 2016;38:1115–1121.
   PubMed Web of Science ®Google Scholar
• Fujino T, Sakamaki R, Ito H, et al. Farnesoid X receptor regulates the growth of renal adenocarcinoma cells without affecting that of a normal renal cell-derived cell line. J Toxicol Sci. 2017;42:259–265.
   PubMed Web of Science ®Google Scholar
• Theocharis S, Masaoutis C, Giaginis C, et al. Clinical significance of farnesoid X receptor expression in renal cell carcinoma. Poster session presented at: 30th European Congress of pathology; 2018 Sep 8–12; Bilbao, Spain. Virchows Arch. 2018;473(Suppl1):1.
   Google Scholar
• Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–180.
   PubMed Web of Science ®Google Scholar
• Levi M. Role of bile acid–regulated nuclear receptor FXR and G protein–coupled receptor TGR5 in regulation of cardiorenal syndrome (Cardiovascular disease and chronic kidney disease). Hypertension. 2016;67:1080–1084.
   PubMed Web of Science ®Google Scholar
• Renga B, Mencarelli A, Vavassori P, et al. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta. 2010;1802:363–372.
   PubMed Web of Science ®Google Scholar
• Dufer M, Horth K, Wagner R, et al. Bile acids acutely stimulate insulin secretion of mouse -cells via farnesoid X receptor activation and KATP channel inhibition. Diabetes. 2012;61:1479–1489.
   PubMed Web of Science ®Google Scholar
• Popescu IR, Helleboid-Chapman A, Lucas A, et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett. 2010;584:2845–2851.
   PubMed Web of Science ®Google Scholar
• Ghebremariam YT, Yamada K, Lee JC, et al. FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats. PLoS One. 2013;8:e60653.
   PubMed Web of Science ®Google Scholar
• Sydow K, Mondon CE, Schrader J, et al. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol. 2008;28:692–697.
   PubMed Web of Science ®Google Scholar
• Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146:984–991.
   PubMed Web of Science ®Google Scholar
• Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116:1102–1109.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006–1011.
   PubMed Web of Science ®Google Scholar
• Prawitt J, Abdelkarim M, Stroeve JHM, et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes. 2011;60:1861–1871.
   PubMed Web of Science ®Google Scholar
• Langhi C, Le May C, Kourimate S, et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett. 2008;582:949–955.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jones PJH, Woollett LA, et al. Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans. Transl Res. 2006;148:37–45.
   PubMed Web of Science ®Google Scholar
• Pérez-Aguilar F, Bretó M, Alegre B, et al. Increase in serum total cholesterol and low-density lipoprotein cholesterol by high-dose chenodeoxycholic acid in patients with radiolucent gallstones significantly reversed during preventive low dose after gallstone dissolution. Digestion. 1985;31:225–233.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–582.e1.
   PubMed Web of Science ®Google Scholar
• Mu J, Feng B, Ye Z, et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol. 2011;24:177–184.
   PubMed Web of Science ®Google Scholar
• Zhou B, Feng B, Qin Z, et al. Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy. Mol Cell Endocrinol. 2016;419:72–82.
   PubMed Web of Science ®Google Scholar
• Kang YS, Lee MH, Song HK, et al. Chronic administration of visfatin ameliorated diabetic nephropathy in type 2 diabetic mice. Kidney Blood Press Res. 2016;41:311–324.
   PubMed Web of Science ®Google Scholar
• Fickert P, Krones E, Pollheimer MJ, et al. Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology. 2013;58:2056–2069.
   PubMed Web of Science ®Google Scholar
• Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A. 2004;101:3668–3673.
   PubMed Web of Science ®Google Scholar
• Li J, Wilson A, Kuruba R, et al. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res. 2008;77:169–177.
   PubMed Web of Science ®Google Scholar
• Zhang R, Ran -H-H, Zhang Y-X, et al. Farnesoid X receptor regulates vascular reactivity through nitric oxide mechanism. J Physiol Pharmacol. 2012;63:367–372.
   PubMed Web of Science ®Google Scholar
• Kida T, Murata T, Hori M, et al. Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2009;296:H195–H201.
   PubMed Web of Science ®Google Scholar
• Li J, Wilson A, Gao X, et al. Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine. J Pharmacol Exp Ther. 2009;331:234–243.
   PubMed Web of Science ®Google Scholar
• Miyazaki-AnzaiS, LeviM, Kratzer A, et al. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease. Circ Res. 2010;106:1807–1817.
   PubMed Web of Science ®Google Scholar
• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–272.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Chapter 3: management of progression and complications of CKD. Kidney Int Suppl. 2013;3:73–90.
   Google Scholar
• Armstrong LE, Guo GL. Role of FXR in liver inflammation during nonalcoholic steatohepatitis. Curr Pharmacol Rep. 2017;3:92–100.
   PubMedGoogle Scholar
• Xu W, Lu C, Zhang F, et al. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction. FEBS J. 2017;284:114–133.
   PubMed Web of Science ®Google Scholar
• Gai Z, Visentin M, Gui T, et al. Effects of farnesoid X receptor activation on arachidonic acid metabolism, NF-kB signaling, and hepatic inflammation. Mol Pharmacol. 2018;94:802–811.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Goto T, Itoh M, Suganami T, et al. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. Sci Rep. 2018;8:8157.
   PubMed Web of Science ®Google Scholar
• Comeglio P, Filippi S, Sarchielli E, et al. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. J Steroid Biochem Mol Biol. 2017;168:26–37.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu X, Wang B, et al. Farnesoid X receptor deletion improves cardiac function, structure and remodeling following myocardial infarction in mice. Mol Med Rep. 2017;16:673–679.
   PubMed Web of Science ®Google Scholar
• Gai Z, Hiller C, Chin SH, et al. Uninephrectomy augments the effects of high fat diet induced obesity on gene expression in mouse kidney. Biochim Biophys Acta. 2014;1842:1870–1878.
   PubMed Web of Science ®Google Scholar
• Wang XX, Luo Y, Wang D, et al. A dual agonist of farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice. J Biol Chem. 2017;292:12018–12024.
   PubMed Web of Science ®Google Scholar
• Arsenijevic D, Cajot J-F, Fellay B, et al. Uninephrectomy-induced lipolysis and low-grade inflammation are mimicked by unilateral renal denervation. Front Physiol. 2016;7:227.
   PubMed Web of Science ®Google Scholar
• Glastras SJ, Wong MG, Chen H, et al. FXR expression is associated with dysregulated glucose and lipid levels in the offspring kidney induced by maternal obesity. Nutr Metab. 2015;12:40.
   Google Scholar
• OCALIVA 10mg film-coated tablets - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. [ cited 2018 Aug 14]. Available from: https://www.medicines.org.uk/emc/product/7630/smpc.
   Google Scholar
• Sepe V, Distrutti E, Fiorucci S, et al. Farnesoid X receptor modulators 2014-present: a patent review. Expert Opin Ther Pat. 2018;28:351–364.
   PubMed Web of Science ®Google Scholar